Wednesday, 12 March 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 12 March 2025
News

Multi-billion dollar hopeful falters

 Posted 12 March 2025 AM

Less than two years ago it was touted as a potential multi-billion-dollar product but Johnson & Johnson has announced it will stop developing its drug aticaprant as an add-on therapy for patients with major depressive order.

The company said it had decided to discontinue the Phase 3 Ventura development program "due to insufficient efficacy in the target patient population". It underlined the data confirmed aticaprant is safe and well-tolerated, and no new safety signals were identified.

To see the whole article, please login

Popular

40-year-old pharma rebrands
Which Aussie pharma pays most?
Three brands hit with first generic
Multi-billion dollar hopeful falters
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (36)

Clinical & Medical, R&D (16)

Regulatory, Pharmacovigilance & QA (1)

Other (20)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home